Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously Untreated Patients With Extensive Stage Small Cell Lung Cancer: A north central cancer treatment group study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 4, 2010, Pages 353-357

  Bryce, Alan H ^a,i   Mattar, Bassam ^b   Hillman, Shauna L ^a   Adjei, Alex A ^c   Kugler, John W ^d   Rowland Jr , Kendrith ^e   Wender, Donald B ^f   Soori, Gamini ^g   Perez, Edith A ^h   Jett, James R ^a  

^a MAYO CLINIC   (United States)

^b WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Illinois Oncology Research Association CCOP   (United States)

^e Carle Cancer Center CCOP   (United States)

^f Siouxland Hematology Oncology Associates   (United States)

^g MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^h MAYO CLINIC   (United States)

ⁱ Santa Barbara Hematology Oncology   (United States)

Author keywords

Filgastrim; Phase II; Small cell lung cancer; Topotecan

Indexed keywords

CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOTENSION; HYPOXIA; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; AGED; DISEASE FREE SURVIVAL; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SMALL CELL CARCINOMA; SURVIVAL; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; CARBOPLATIN; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TIME FACTORS; TOPOTECAN; TREATMENT OUTCOME;

EID: 77956639562     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181b0c27f     Document Type: Article

References (26)

1. Choi NC, Carey RW, Kaufman SD, et al. Small cell carcinoma of the lung: A progress report of 15 years' experience. Cancer. 1987;59:6-14.
2. Maksymiuk AW, Jett JR, Earle JD, et al. Sequencing and schedule effects of cisplatin plus etoposide in small cell lung cancer: Results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol. 1994;12: 70-76.
3. Morstyn G, Ihde DC, Lichter AS, et al. Small cell lung cancer 1973-1983: Early progress and recent obstacles. Int J Radiat Oncol Biol Phys. 1984;10: 515-539.
4. Sorensen M, Lassen U, Palshof T, et al. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial. Lung Cancer. 2008;60:252-258.
5. Murray N, Turrisi AT III. A review of first-line treatment for small cell lung cancer. J Thorac Oncol. 2006;1:270-278.
6. Chute JP, Venzon DJ, Hankins L, et al. Outcome of patients with small cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc. 1997;72:901-912.
7. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial. J Clin Oncol. 1996;14:2345-2352.
8. Ramalingam S, Belani CP, Day R, et al. Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small cell lung cancer. Ann Oncol. 2004;15:247-251.
9. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small cell lung cancer. J Clin Oncol. 2001;19:1743-1749.
10. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med. 2002;346:85-91.
11. de Jonge MJ, Loos WJ, Gelderblom H, et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects. J Clin Oncol. 2000;18:2104-2115.
12. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small cell lung cancer: A Hellenic Co-operative Oncology Group study. Ann Oncol. 1994;5: 601-607.
13. Kaplan E, Meier P. Nonparametric estimation of incomplete estimations. J Am Stat Assoc. 1958;53:457-481.
14. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small cell lung cancer. J Clin Oncol. 2006;24:2044-2051.
15. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer. J Clin Oncol. 2006; 24:2038-2043.
16. Natale RB, Lara PN, Chansky K, et al. S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (ESCLC) [abstract 7512]. J Clin Oncol. 2008;26(suppl 15):400s.
17. Jett JR, Hatfield AK, Hillman S, et al. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: A phase II trial of the North Central Cancer Treatment Group. Cancer. 2003;97:2498-2503.
18. Lyss AP, Herndon JE II, Lynch TJ Jr, et al. Novel doublets in extensive-stage small cell lung cancer: A randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer. 2002;3:205-210; discussion 11-12.
19. Hainsworth JD, Morrissey LH, Scullin DC Jr, et al. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Cancer. 2002;94: 2426-2433.
20. Hoskins P, Eisenhauer E, Vergote I, et al. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2000;18:4038-4044.
21. Pentheroudakis G, Briasoulis E, Karavassilis V, et al. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: Parallel topotecan escalation in two fixed platinum dosing schemes. Chemotherapy. 2005;51:154-161.
22. Vecchione F, Fruscio R, Dell'Anna T, et al. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:367-372.
23. Koensgen D, Stengel D, Belau A, et al. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: Phase I/II study. Cancer Chemother Pharmacol. 2008;62:393-400. (Pubitemid 351871797)
24. Sorensen M, Lassen U, Jensen PB, et al. Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease. J Thorac Oncol. 2008;3:902-906.
25. Aoe K, Kiura K, Ueoka H, et al. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines. Anticancer Res. 2004;24:3893-3897.
26. van Waardenburg RC, de Jong LA, van Eijndhoven MA, et al. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J Biol Chem. 2004;279:54502-54509.